Policy # Policy Title Print View
MP-011 Genetic Testing for Alzheimer Disease
MP-097 In Vitro Chemoresistance and Chemosensitivity Assays
MP-133 Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment
MP-136 Genetic Testing for Non-Cancerous Inheritable Diseases
MP-162 Pharmacogenomic and Metabolite Markers for Patients Treated with Thiopurines
MP-180 Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
MP-253 Laboratory and Genetic Testing for Use of 5-Fluorouracil (5-FU) in Patients with Cancer
MP-256 Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)
MP-285 Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease
MP-342 Gene Expression- Based Assays Testing for Cancers of Unknown Primary
MP-365 KRAS, NRAS and BRAF Variant Analysis in Metastatic Colorectal Cancer
MP-405 JAK2, MPL, and CALR Testing for Myeloproliferative Neoplasms
MP-416 Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
MP-422 Use of Common Genetic Variants (Single-Nucleotide Variants) to Predict Risk of Nonfamilial Breast Cancer
MP-425 Cytochrome P450 Genotype-Guided Treatment Strategy
MP-426 Multi-marker Serum-Testing Related to Ovarian Cancer
MP-466 KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy
MP-468 Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC)
MP-474 Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment
MP-487 Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers
MP-513 Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
MP-516 Molecular Markers in Fine Needle Aspirates of the Thyroid
MP-519 Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell Free Fetal DNA
MP-525 Genotype-Guided Warfarin Dosing
MP-532 Genetic Cancer Susceptibility Panels Using Next Generation Sequencing
MP-533 BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
MP-534 Genetic Testing for the Diagnosis and Risk Assessment of Prostate Cancer
MP-538 Cardiovascular Risk Panels
MP-539 Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders
MP-540 Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies
MP-541 BRAF Gene Variant Testing To Select Melanoma or Glioma Patients for Targeted Therapy
MP-542 Genotyping for 9p21 Single Nucleotide Polymorphisms to Predict Risk of Cardiovascular Disease or Aneurysm
MP-543 Genetic Testing for Alpha-1 Antitrypsin Deficiency
MP-544 Molecular Testing for the Management of Pancreatic Cysts, Barrett Esophagus, and Solid Pancreatic Lesions
MP-545 Human Leukocyte Antigen (HLA) Testing for Celiac Disease
MP-546 Genetic Testing for Hereditary Hemochromatosis
MP-547 DNA-Based Testing for Adolescent Idiopathic Scoliosis
MP-549 Gene Expression Testing in the Evaluation of Patients with Stable Ischemic Heart Disease
MP-550 Genetic Testing for Diagnosis and Management of Mental Health Conditions
MP-551 Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification
MP-553 Genetic Testing for Macular Degeneration
MP-554 Noninvasive Fetal RHD Genotyping Using Cell-Free Fetal DNA
MP-559 Genetic Testing for Epilepsy
MP-562 Multianalyte Assays With Algorithmic Analyses for Predicting Risk of Type 2 Diabetes
MP-567 Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
MP-570 Proteomic Testing for Systemic Therapy in Non-Small Cell Lung Cancer
MP-571 Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
MP-580 Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related Disorders
MP-581 Genetic Testing for PTEN Hamartoma Tumor Syndrome
MP-582 Analysis of MGMT Promoter Methylation in Malignant Gliomas
MP-583 Genetic Testing for FLT3, NPM1 and CEBPA Variants in Cytogenetically Normal Acute Myeloid Leukemia
MP-585 Gene Expression Profiling for Uveal Melanoma
MP-586 Genotype-Guided Tamoxifen Treatment
MP-587 Multigene Expression Assay for Predicting Recurrence in Colon Cancer
MP-588 Genetic Testing for Lactase Insufficiency
MP-589 Genetic Testing of CADASIL Syndrome
MP-590 Genetic Testing for Hereditary Pancreatitis
MP-591 Genetic Testing for Familial Cutaneous Malignant Melanoma
MP-593 Preimplantation Genetic Testing
MP-594 Pharmacogenetic Testing for Pain Management
MP-595 Genetic Testing for the Diagnosis of Inherited Peripheral Neuropathies
MP-601 Genetic Testing for Mitochondrial Disorders
MP-602 Genetic Testing for Li-Fraumeni Syndrome
MP-606 Genetic Testing for FMR1 Variants (Including Fragile X Syndrome)
MP-608 Genetic Testing for Statin-Induced Myopathy
MP-609 Moderate Penetrance Variants Associated With Breast Cancer in Individuals at High Breast Cancer Risk
MP-614 Genetic Testing for CHARGE Syndrome
MP-620 Genetic testing for Neurofibromatosis
MP-628 Chromosomal Microarray Testing for the Evaluation of Pregnancy Loss
MP-630 Proteogenomic Testing for Patients with Cancer
MP-640 Genetic Testing for Duchenne and Becker Muscular Dystrophy
MP-641 Genetic Testing for Limb-Girdle Muscular Dystrophies
MP-642 Genetic Testing for Facioscapulohumeral Muscular Dystrophy
MP-643 Genetic Testing for Hereditary Hearing Loss
MP-644 Molecular Testing in the Management of Pulmonary Nodules
MP-649 Genetic Testing for Fanconi Anemia
MP-700 Genetic Testing for Rett Syndrome
MP-701 Genetic testing for Heterozygous Familial Hypercholesterolemia
MP-720 Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
MP-722 Next-Generation Sequencing for the Assessment of Measurable Residual Disease